Patents by Inventor Philippe Nakache

Philippe Nakache has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACSS2 inhibitors and methods of use thereof
    Patent number: 12133852
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: November 5, 2024
    Assignee: EpiVario, Inc.
    Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
  • ACSS2 inhibitors and methods of use thereof
    Patent number: 10851064
    Abstract: The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: December 1, 2020
    Assignee: METABOMED LTD.
    Inventors: Philippe Nakache, Omri Erez, Simone Botti, Andreas Goutopoulos
  • Pyrimidine derivatives as POSH and POSH-AP inhibitors
    Patent number: 8283355
    Abstract: Pyrimidine deriviatives are ubiquination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, are useful for the treatment of viral infections and neurological disorders.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: October 9, 2012
    Assignee: Proteologics, Ltd.
    Inventors: Philippe Nakache, Itzchak Angel, Nurit Livnah, Maxim Borovitov
  • PYRIMIDINE AND PYRIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS
    Publication number: 20120015967
    Abstract: Pyridine and pyrimidine derivatives inhibit ubiquitination of human polypeptides, particularly of POSH and POSH-associated proteins such as HERPUD1, and can be used as medicaments for treatment of viral infections caused by virus such as HIV and for treatment of neurological disorders or diseases.
    Type: Application
    Filed: August 21, 2008
    Publication date: January 19, 2012
    Applicant: PROTEOLOGICS, LTD.
    Inventors: Philippe Nakache, Nurit Livnah
  • Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
    Patent number: 8067473
    Abstract: Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amount of a topoisomerase inhibitor, wherein the treatment with the E3 ubiquitin ligase inhibitor and topoisomerase inhibitor modulates cell growth in comparison to a cell treated with the topoisomerase inhibitor alone. The present invention further provides methods for identifying and making an E3 ubiquitin ligase inhibitor.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: November 29, 2011
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventors: Omri Erez, Iris Alchanati, Philippe Nakache
  • PYRIMIDINE DERIVATIVES AS POSH AND POSH-AP INHIBITORS
    Publication number: 20100179178
    Abstract: Pyrimidine deriviatives are ubiquination inhibitors that inhibit the ubiquitin ligase activity, particularly of POSH polypeptides, are useful for the treatment of viral infections and neurological disorders.
    Type: Application
    Filed: November 7, 2007
    Publication date: July 15, 2010
    Applicant: Proteologics Ltd
    Inventors: Philippe Nakache, Itzchak Angel, Nurit Livnah, Maxim Borovitov
  • Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
    Publication number: 20080227727
    Abstract: Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amount of a topoisomerase inhibitor, wherein the treatment with the E3 ubiquitin ligase inhibitor and topoisomerase inhibitor modulates cell growth in comparison to a cell treated with the topoisomerase inhibitor alone. The present invention further provides methods for identifying and making an E3 ubiquitin ligase inhibitor.
    Type: Application
    Filed: January 16, 2008
    Publication date: September 18, 2008
    Inventors: Omri Erez, Iris Alchanati, Philippe Nakache